FDA grants traditional approval to Retevmo for RET fusion-positive solid tumors

The FDA has granted traditional approval to selpercatinib for adults and children aged 2 years and older with locally advanced or metastatic solid tumors with a RET gene fusion.Selpercatinib (Retevmo, Eli Lilly & Co.), an oral kinase inhibitor, received approval for treatment of patients with RET fusion-positive tumors, as detected by an FDA-approved test, who have progressed on or following